NCT05804032 2026-02-18
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
Phase 3 Completed
Clinical Trials
45 trialsNCT01208766 2026-01-06
HO95
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Completed
NCT02252172 2025-10-20
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT01650701 2025-09-25
RELEVANCE
The Lymphoma Academic Research Organisation
Phase 3 Completed
NCT01996865 2025-07-10
MAGNIFY
Celgene
Phase 3 Completed
NCT03941860 2025-05-23
Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
National Cancer Institute (NCI)
Phase 3 Completed
NCT01476787 2025-05-14
RELEVANCE
Celgene
Phase 3 Completed
NCT02076009 2025-05-01
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT01093196 2024-11-07
Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT01091831 2024-11-06
Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT03859427 2024-08-13
ARROW2
Amgen
Phase 3 Completed
NCT00551928 2024-07-22
MPRvsMEL200
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT03952091 2024-07-03
TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
TJ Biopharma Co., Ltd.
Phase 3 Completed
NCT02285062 2023-06-22
ROBUST
Celgene
Phase 3 Completed
NCT01564537 2023-03-10
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Takeda
Phase 3 Completed
NCT01090089 2023-02-23
DSM XIII
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Phase 3 Completed
NCT01938001 2023-02-22
AUGMENT
Celgene
Phase 3 Completed
NCT01335399 2022-09-30
ELOQUENT - 1
Bristol-Myers Squibb
Phase 3 Completed
NCT01239797 2022-06-01
ELOQUENT - 2
Bristol-Myers Squibb
Phase 3 Completed
NCT01556776 2022-01-05
A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy
German CLL Study Group
Phase 3 Completed
NCT01109004 2021-12-09
BMT CTN 0702
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT00774345 2021-12-02
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy
Celgene
Phase 3 Completed
NCT02495922 2021-09-10
GMMG-HD6
University of Heidelberg Medical Center
Phase 3 Completed
NCT01122472 2021-07-26
REMARC
The Lymphoma Academic Research Organisation
Phase 3 Completed
NCT02112175 2021-04-14
ARUMM
Celgene
Phase 3 Completed
NCT02128061 2021-04-13
Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+
The Lymphoma Academic Research Organisation
Phase 3 Completed
NCT02322320 2020-05-11
Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT00622336 2019-11-20
A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma
Celgene
Phase 3 Completed
NCT00689936 2019-11-20
FIRST
Celgene
Phase 3 Completed
NCT00928486 2019-11-20
A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma
Celgene
Phase 3 Completed
NCT00057616 2019-11-08
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.
Celgene
Phase 3 Completed
NCT00910910 2019-07-09
ORIGIN
Celgene
Phase 3 Completed
NCT01191060 2019-04-18
IFM/DFCI2009
University Hospital, Toulouse
Phase 3 Completed
NCT01243944 2019-03-06
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
Incyte Corporation
Phase 3 Completed
NCT00988208 2018-04-04
Mainsail
Celgene
Phase 3 Completed
NCT00891384 2018-01-19
Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Phase 3 Completed
NCT02406144 2017-11-30
Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma
PETHEMA Foundation
Phase 3 Completed
NCT01916252 2017-09-27
GEM2012MENOS65
PETHEMA Foundation
Phase 3 Completed
NCT01530594 2016-02-25
Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma
King Faisal Specialist Hospital & Research Center
Phase 3 Completed
NCT01621672 2015-10-19
UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma
University of Arkansas
Phase 3 Completed
NCT00064038 2015-03-25
S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma
SWOG Cancer Research Network
Phase 3 Completed
NCT00420849 2012-05-21
A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
Celgene
Phase 3 Completed
NCT00478777 2011-11-03
A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
Celgene
Phase 3 Completed
NCT00093028 2010-07-02
Study of Bortezomib and Revlimidâ„¢ for Patients Relapsing or Progressing on Total Therapy II
University of Arkansas
Phase 3 Completed
NCT00179647 2010-03-16
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
Celgene
Phase 3 Completed